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HLA-G*0105N Null Allele Encodes Functional HLA-G Isoforms1
Magali Le Discorde,2 Caroline Le Danff, Philippe Moreau, Nathalie Rouas-Freiss, and Edgardo D. Carosella
Service de Recherches en He´mato-Immunologie, CEA-DSV-DRM, Institut d’He´matologie, Hoˆpital Saint-Louis,
Paris 75010, France
ABSTRACT
Expression of the nonclassical HLA class I antigen, HLA-G, is
associated with immune tolerance in view of its role in main-
taining the fetus in utero, allowing tumor escape, and favoring
graft acceptance. Expressed on invasive trophoblast cells, HLA-
G molecules bind inhibitory receptors on maternal T lympho-
cytes and NK cells, thereby blocking their cytolytic activities and
protecting the fetus from maternal immune system attack. The
HLA-G gene consists of 15 alleles, including a null allele, HLA-
G*0105N. HLA-G*0105N presents a single base deletion, pre-
venting translation of both membrane-bound (HLA-G1) and full-
length soluble isoforms (HLA-G5) as well as of the spliced HLA-
G4 isoform. The identification of healthy subjects homozygous
for this HLA-G null allele suggests that the HLA-G*0105N allele
may generate other HLA-G isoforms, such as membrane-bound
HLA-G2 and -G3 and the soluble HLA-G6 and -G7 proteins,
which may substitute for HLA-G1 and -G5, thus assuming the
immune tolerogeneic function of HLA-G. To investigate this
point, we cloned genomic HLA-G*0105N DNA and transfected
it into an HLA-class I-positive human cell line. The results ob-
tained indicated that HLA-G proteins were indeed present in
HLA-G*0105N-transfected cells and were able to protect against
NK cell lysis. These findings emphasize the role of the other
HLA-G isoforms as immune tolerogeneic molecules that may
also contribute to maternal tolerance of the semiallogenic fetus
as well as tumor escape and other types of allogeneic tissue
acceptance.
embryo, gene regulation, immunology, implantation, pregnancy
INTRODUCTION
Protection of the semiallogenic fetus against maternal
immune recognition and attack has been attributed princi-
pally to the high and almost unique expression of human
leukocyte antigen-G (HLA-G) on trophoblast cells at the
fetal-maternal interface [1]. The nonclassical HLA-G gene
is characterized by alternative splicing that yields seven
proteins, four membrane bound (HLA-G1 through -G4) and
three soluble (HLA-G5 through -G7). Full-length HLA-G
mRNA encodes the HLA-G1 protein, which has three ex-
tracellular globular domains, one membrane-anchored do-
main, and one intracytoplasmic domain. Exons 3 and/or 4
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may be deleted from the primary transcript, yielding the
alternative mRNA HLA-G2, HLA-G3, and HLA-G4 forms.
In addition, the insertion of introns 2 or 4 may generate
soluble isoforms, such as HLA-G5 (the soluble full-length
HLA-G1 counterpart), HLA-G6 (the soluble HLA-G2
counterpart), and HLA-G7 (the soluble HLA-G3 counter-
part) (reviewed in [2]). The structures of both membrane-
bound HLA-G1 and soluble HLA-G5 proteins are similar
to those of classical class I proteins, consisting of three
extracellular domains linked to b2-microglobulin (b2m).
Functional assays have demonstrated that both mem-
brane-bound and soluble HLA-G proteins are able to inhibit
NK cell and antigen-specific T-cell cytotoxicity [3, 4] and
the proliferation of allogeneic T cells [5–7]. Moreover, sol-
uble HLA-G is able to induce apoptosis of both activated
CD81 T and NK cells [8, 9].
The identification of these seven HLA-G protein iso-
forms suggested that HLA-G provides multiple functions at
the immune-privileged sites where they are expressed, such
as the fetal-maternal interface, the thymus, and the cornea
[10–12]. On the other hand, in the absence of a given HLA-
G isoform, this redundancy may serve to maintain the im-
mune tolerogenic function provided by one or more of the
other HLA-G isoforms.
The HLA-G gene consists of 15 alleles, including the
HLA-G*0105N null allele, which is characterized by a sin-
gle base-pair deletion in exon 3 [13]. This deletion of a
single cytosine at codon 130 results in a gap in the open
reading frame, causing a premature stop at either codon 189
(TGA) near the beginning of exon 4, which blocks trans-
lation of HLA-G1 and -G5, or codon 297 (TAG) in exon
5, blocking the translation of HLA-G4. However, HLA-
G*0105N is able to maintain translation of both the mem-
brane-bound HLA-G2 and -G3 proteins and the soluble
HLA-G6 and -G7 proteins, in all of which exon 3, con-
taining the deletion, is removed by alternative splicing (Fig.
1).
The HLA-G*0105N null allele has been described in
healthy adults whose own gestations and deliveries were
normal (without complications). The detection of individ-
uals who are genetically homozygous for the HLA-
G*0105N allele suggests that the HLA-G isoforms encoded
by this allele possess functions able to compensate for the
absence of both the HLA-G1 and -G5 proteins and to main-
tain the immune privileged status of the fetal-maternal in-
terface [14, 15].
Based on the previously mentioned observations and on
a previous study showing that selection may have increased
the frequency of the HLA-G*0105N allele [16], the goal of
the present study was to demonstrate that in the absence of
the HLA-G1, -G5, and -G4 isoforms, the other HLA-G iso-
forms present in HLA-G*0105N can indeed provide a pro-
tective function.
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In the present work, we investigate the structural and
functional aspects of HLA-G*0105N proteins. We con-
structed the HLA-G*0105N null allele genomic DNA in the
pcDNA3.1 expression vector, which enabled us to study the
expression and function of its proteins. The aim of this
work was to acquire more data on spliced HLA-G isoforms
in general and to understand how they could compensate
for the absence of full-length HLA-G proteins.
MATERIALS AND METHODS
In Vitro Site-Directed Mutagenesis
In vitro site-directed mutagenesis was carried out using the Stratagene
QuickChange XL site-directed mutagenesis kit, which allows site-specific
mutation in double-stranded plasmids. The plasmid DNA template (50 ng)
HLA-G*010102-pcDNA3.1, isolated from the dam1 JM109 Escherichia
coli strain, was replicated by PfuTurbo DNA polymerase (2.5 U) using
two synthetic primers, G.Null S and G.Null AS (125 ng each), consisting
of 15 bases on both sides of the DC mutation. The oligonucleotide primers,
each complementary to opposite strands of the HLA-G*010102 insert,
were extended during temperature cycling (958C for 1 min; 18 cycles at
958C for 50 sec, 608C for 50 sec, 688C for 15 min) and terminated by 7
min at 688C. Following temperature cycling, amplification reactions were
cooled and digested for 1 h at 378C using Dpn I restriction enzyme to
eliminate the nonmutated parental supercoiled double-stranded DNA. At
this step, genomic HLA-G*010102-pcDNA3.1 was replaced by genomic
HLA-G*0105N-pcDNA3.1. The mutated DNA was then transformed in
XL10-Gold ultracompetent cells.
Cell Lines, Transfection, and Cultures
Melanoma M8 (kindly provided by F. Jotereau, INSERM U211,
Nantes, France) and histiocytic lymphoma U937 (American Type Culture
Collection) human cell lines are HLA-class II negative; HLA-A, -B, -C,
and -E positive (HLA-A1, -A2, -B12, and B40/male); but HLA-G nega-
tive. The NKL NK cell line (kindly provided by E.H. Weiss, Department
of Anthropology and Human Genetics, Munich, Germany) [17, 18] and
the YT2C2 NK [19, 20] subclone (kindly provided by P. Paul, Hospital
Saint-Louis, Paris, France) have been previously described. All cells were
maintained in RPMI 1640 plus Glutamax medium supplemented with 1
mg/ml gentamicin, fungizone, and 20% inactivated fetal calf serum. NKL
cells were concurrently cultured in the presence of 50 U/ml of interleukin-
2 (IL2) (Sigma-Aldrich, St. Quentin Fallavier, France) and boosted to 100
U/ml IL2 the day before the cytotoxicity assays. M8 and U937 transfec-
tants were selected using 200 mU/ml hygromycin B (Invitrogen, Cergy
Pontoise, France). HLA-G*0105N inserted into the pcDNA3.1/Hygro (-)
expression vector was transfected into M8 and U937 cells. We worked
with bulk transfectants since absence of the HLA-G1 membrane-bound
isoform prevents the selection of positive cloned cells by cell sorting. The
other transfectants, M8-HLA-G1 through -G4 and M8-HLA-G*010102,
have been previously characterized [21, 22].
Classical and Real-Time RT-PCR Analysis
Reverse transcription-polymerase chain reaction (RT-PCR) was carried
out to validate HLA-G expression and to determine which isoforms were
expressed in our new M8-HLA-G*0105N cell line. Total RNA was purified
by RNA-WIZ reagent (Ambion, Huntingdon, U.K.) according to the man-
ufacturer’s instructions. The cDNA was synthesized on 5 mg RNA using
oligo (dT) primers (Invitrogen) and MMLV-reverse transcriptase (Life
Technologies, Cergy-Pontoise, France) for 1 h at 428C. Heating for 8 min
at 958C stopped the reaction.
Real-time PCR (ABI PRISM 7000 SDS) was used to determine the
quantities of HLA-G transcripts in transfected cell lines. Duplex PCR was
carried out for 40 amplification rounds in the presence of TaqMan Uni-
versal PCR Master Mix, using the TaqMan Assay Reagent and GAPDH
as an endogenous control (probe with VIC reporter and TAMRA quench-
er), HLA-G-specific probe (200 nM, FAM reporter, and TAMRA quench-
er), and HLA-G-specific primers (300 mM, Q biogen).
Classical PCR was carried out according to the 13th HLA Workshop
[21] procedure, using a Perkin-Elmer DNA thermal cycler in a total vol-
ume of 100 ml containing 2 ml of the RT reaction product, 200 mM of
each dNTP (Invitrogen), 100 ng of each primer, 10 ml of 103 Taq buffer,
and 2.5 U of Taq polymerase (Applied Biosystems, Courtabœuf, France).
All HLA-G isoforms were amplified with G.257F/G.1004R primers, HLA-
G2 with G.-3/G.1216 primers, HLA-G3 with G.-3-4/G.1216 primers, and
HLA-G5 with G.257/G.i4. These PCR products were revealed by radio-
active hybridization with G.927 oligonucleotide, except for HLA-G5 am-
plification, which was revealed using the G.R probe.
Vector Construction and Oligonucleotides
In vitro site-directed mutagenesis was accomplished from the genomic
HLA-G*010102 sequence inserted into pcDNA3.1/Hygro (-) expression
vector (Invitrogen). The HLA-G*010102 sequence begins in the promoter
at the XbaI site (460 nucleotides upstream from ATG) and continues to
the EcoRV site in the 39UT [21]. The cytosine deletion was introduced
using two primers, G.Null S (59-GCCCTGAACGAGGACTGCGCTCCT
GGACCG) and G.Null AS (59-CGGTCCAGGAGCGCAGTCCTCGTTC
AGGGC).
Real-time PCR was carried out with the G.948 forward primer located
in exon 5 (59-CTGGTTGTCCTTGCAGCTGTAG), the G.1002 reverse
primer located in both sides of exon 5 and exon 6 (59-CCTTTTCAATCTG
AGCTCTTCTTTCT), the G.971F internal probe (59-CACTGGAGCTGC
GGTCGCTGCT), the FAM reporter, and the TAMRA quencher.
For classical PCR, all HLA-G transcripts were amplified from exon 2
by G.257 forward (59-GGAAGAGGAGACACGGAACA) to exon 5/6 by
G.1004 reverse (59-CCTTTTCAATCTGAGCTCTTCTTT). HLA-G2 and
HLA-G3 transcripts were amplified, respectively, from exons 2/4 by G.-3
forward (59-ACCAGAGCGAGGCCAACCCC) and from exons 2/5 by G.-
3-4 forward (59-ACCAGAGCGAGGCCAAGCAG) to the 39UT sequence
by G.1216 reverse (59-GACGGAGACATCCCAGCCCC). Transcripts cor-
responding to soluble forms were amplified from exon 2 by G.257 up to
intron 4 by G.i4 reverse (59- CTGGGAAAGGAGGTGAAGGT). Internal
probes were localized in exon 5 with G.927 reverse (59-CCAGCAAC-
GATACCCATGAT) or in exon 2 with G.R (59-GGTCTGCAGGTT-
CATTCTGTC).
Monoclonal Antibodies
The following murine antibodies were used: 4H84, IgG1 recognizing
a1 domain common to all HLA-G isoforms (provided by Michael Mc-
Master [23]); MEM-G/04, IgG1 recognizing the denatured form of HLA-
G1, -G2, -G5, and -G6 (provided by Vaclav Horejsi, Prague, Czech Re-
public); MEM-G/09, IgG1 recognizing the HLA-G molecules associated
with beta2-microglobulin (HLA-G1 and -G5) [24] (Exbio, Prague, Czech
Republic); 5A6G7, IgG1 antibody against intron 4 of soluble HLA-G5
and -G6 isoforms made in our laboratory [25].
Immunocytochemical Analysis
Cells were grown on LabTech slides (Dutscher, Brumath, France), fixed
in acetone, and stored at 2808C until evaluation of the expression of HLA-
G and class I protein by immunohistochemistry, using the Ultra-Tech HRP
Streptavidin-Biotin Universal Detection System (Immunotech Coulter,
Roissy, France) as previously described [12]. Briefly, endogenous perox-
idase was blocked with 3% H2O2, and antibodies were diluted in buffer
containing 0.1% saponin.
Flow Cytometry Assays
The flow cytometry technique was used to analyze cell-surface HLA-
G protein expression. Transfected cells were phenotyped according to stan-
dard procedure by incubating them with the primary anti-HLA-G antibody
MEM-G/09 in PBS 2% heat-inactivated fetal calf serum for 30 min at 48C.
Cells were subsequently stained with an F(ab9)2 goat anti-mouse IgG an-
tibody conjugated with phycoerythrin (Immunotech Coulter).
Cell-Surface Protein Biotinylation
Cell-surface proteins of viable M8 transfected cells were biotinylated
as previously described [4]. Cells were first washed twice with PBS and
treated with sulfo-NHS-LC-biotin (Pierce, Rockford, IL; 200 mg/ml of
PBS) for 4 min at room temperature. The cells were washed twice with
PBS, treated with 50 mM glycine for 5 min, and again washed twice with
PBS. Dead or dying (nonadherent) cells were removed by washing. Cells
were then detached and collected in tubes, then washed in PBS five times
at 48C. Cells in the last pellet were readied for analysis by immunopre-
cipitation.
Immunoprecipitation of Cell-Surface Proteins
Cells were lysed in 1 ml of lysis buffer (0.5% CHAPS, 50 mM Tris-
HCl). After centrifugation at 14 000 rpm for 30 min at 48C, biotinylated
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FIG. 1. Schematic drawing of the XbaI - EcoRV genomic DNA sequence
of HLA-G. The HLA-G*0105N sequence corresponds to that of HLA-
G*010102, except for the deletion of cytosine, indicated by an arrow in
exon 3 (DC). The HLA-G gene consists of eight exons (E1–E8), correspond-
ing, respectively, to the peptide leader domains (L), a1, a2, and a3, the
transmembrane domain (TM), and the intracytoplasmic domain (cyt). Ex-
ons were separated by introns (i). The HLA-G*0105N gene putatively en-
codes the membrane-bound HLA-G2, -G3, and soluble HLA-G6 and -G7
proteins, in all of which exon 3, which contains the deletion, is deleted.
HLA-G1, -G4, and -G5 might consist of the leader peptide, the complete
a1 domain, the first half of the a2 domain, and a premature end in the
following exon.
FIG. 2. DNA sequencing electropherogram of the HLA-G*010102 allele
(A) and before deletion of the cytosine in exon 3 and after directed mu-
tagenesis, yielding the HLA-G*0105N allele (B).
proteins were precipitated from the supernatant by precipitation with 100
ml of 50% streptavidin-agarose beads (Bio-Rad, Marnes la Coquette,
France) for 1 h at 48C. Nonbiotinylated proteins in the supernatant of the
first centrifugation were taken to be the intracellular material and retained
for Western blot analysis. Bead-bound biotinylated proteins were washed
in three buffers (buffer 1: 0.1% CHAPS, 150 mM NaCl 40 mM, 0.05%
NaN3, and 20 mM Tris-HCl pH7.5; buffer 2: 0.05% CHAPS, 0.1% SDS,
300 mM NaCl, and 10 mM Tris-HCl pH 8; buffer 3: 0.1% CHAPS and
20 mM Tris-HCl pH 7.4). Biotinylated proteins were then resuspended in
60 ml Laemmli buffer 23, and 40 ml of the nonbiotinylated proteins were
mixed with 20 ml Laemmli buffer 63. These two samples were boiled for
5 min and analyzed by Western blot.
Deglycosylation Treatment
Forty microliters of M8 transfectants lysed in 0.5% CHAPS; 50 mM
Tris-HCl pH 7.5 were deglycosylated, using peptide-N-glycosidase F from
flavobacterium, according to Sigma’s instructions (Sigma-Aldrich). The
deglycosylated proteins were examined by Western blot analysis.
Western Blot Analysis
Proteins were loaded and separated on 12% Tris-glycine-SDS poly-
acrylamide gels and electroblotted to nitrocellulose membranes (Hybond,
Amersham Biosciences, Orsay, France). The membranes were probed with
an HLA-G-specific antibody (4H84, MEM-G/04), then revealed with per-
oxidase-conjugated sheep anti-mouse IgG Ab (Sigma-Aldrich). Western
blots were developed by chemiluminescence (Amersham).
Cytotoxicity Assays
The cytolytic activity of the NKL cells and YT2C2 cells used as ef-
fectors (E) was assessed in 4-h 51Cr release assays in which the effector
cells were mixed with 5 3 103 51Cr-labeled transfected-M8 or U937 (T)
(100 mCi 51Cr sodium chromate; 1 Ci 5 37 Gbq; Amersham) at various
E:T ratios, as previously described [4]. The percentage specific lysis was
calculated as follows: % specific lysis 5 [(cpm experimental 2 cpm spon-
taneous release)/(cpm maximum release 2 cpm spontaneous release)] 3
100. Spontaneous release was determined by incubation of labeled target
cells in RPMI 1640 medium supplemented with 10% FCS. Maximum
release was determined by solubilizing target cells in 0.1 N HCl. In all
experiments, spontaneous release was less than 10% of maximum release.
RESULTS
Construction of HLA-G*0105N Null Allele
Genomic DNA
To study proteins encoded by the HLA-G null allele, we
generated a DNA sequence identical to HLA-G*0105N in
the pcDNA 3.1 expression vector. In vitro site-directed mu-
tagenesis of HLA-G*010102 genomic DNA allowed us to
delete the cytosine at position 815 from ATG (exon 1),
yielding the genomic DNA of the HLA-G*0105N allele. We
used the HLA-G*010102 rather than the HLA-G*010101
reference sequence since HLA-G*010102 and -G*0105N
have identical DNA sequences with the exception of the
cytosine deletion at codon 130 [14]. The XbaI-EcoRV
HLA-G*010102 fragment linked into the pcDNA3.1 vector
used as the template is represented in Figure 1, and the
electropherogram of DNA sequences before and after di-
rected mutagenesis demonstrating deletion of the cytosine
in the newly synthesized DNA is shown Figure 2, the re-
maining sequence being identical. The genomic HLA-
G*0105N DNA presented a deletion at codon 130 (CTG →
TGC), which generated a stop codon 171 nucleotides fur-
ther on at codon 189 (GTG → TGA) in exon 4 or 495
nucleotides further on at codon 297 (GTA → TAG) in exon
5. At this step, we had obtained a copy of the HLA-
G*0105N allele of 3932 nucleotides, beginning 460 bp up-
stream from exon 1 and ending 541 bp downstream from
exon 8.
Pattern of mRNA Expression in HLA-G*0105N-
Transfected Cells
Real-time RT-PCR was carried out on mRNA prepared
from M8 cells transfected with both genomic HLA-
G*0105N and HLA-G*010102 as well as mRNA from JEG-
3 cells (Fig. 3). These results revealed that higher levels of
HLA-G transcripts were produced in both M8-HLA-
G*0105N and M8-HLA-G*010102 than in the JEG-3 cells
(JEG-3 is taken as a reference since it is one of the rare
cell lines that constitutively expresses HLA-G proteins).
HLA-G transcript levels measured in the M8-transfected
cells varied according to the particular HLA-G sequence
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FIG. 3. Results of real-time reverse transcription-polymerase chain re-
action (RT-PCR) analysis showing relative quantities of HLA-G transcripts
in M8-HLA-G*0105N, M8-HLA-G*010102, and M8-pcDNA compared
with that of JEG-3 cells (assigned a value of 1).
FIG. 4. Reverse transcription-polymerase chain reaction (RT-PCR) and Southern blot characterization of HLA-G mRNA isoforms in M8-HLA-G*0105N
(a–d). PCR amplifications are carried out using pan-HLA-G primers G.257F/G.1004R (a, e, f); primer set G.-3F/G.1216R, specific for HLA-G2 (b); primer
set G.-3–4F/G.1216R, specific for HLA-G3 (c); and primer set G.257F / G.i4R, specific for both HLA-G5 and -G6 (d). M8-HLA-G*010102 (e) and M8-
pcDNA (f) are, respectively, the positive and negative controls. Southern blots a, b, c, e, and f were hybridized with G.927R (exon 5), and blot d was
hybridized with G.R (exon 2) probes.
transfected, lower levels being found for M8-HLA-
G*0105N than for M8-HLA-G*010102 (Fig. 4). To deter-
mine the mRNA pattern of M8-HLA-G*0105N, we carried
out HLA-G-specific RT-PCR and radioactive hybridization
reactions comparing M8-HLA-G*0105N with M8-HLA-
G*010102. The specific G.927 probe, located in exon 5,
was used to hybridize all PCR products except those of
G.257/G.i4, which were hybridized using the G.R probe,
located in exon 2. The G.257F/G.1004R primers disclosed
four bands, corresponding to the principal mRNAs: HLA-
G5 (889 bp), -G1 (767 bp), -G2 and -G4 (491 bp), and
-G3 (215 bp) (Fig. 4a). HLA-G2 was amplified using the
G.-3/G.1216 primers (627 bp) (Fig. 4b) and HLA-G3 with
the G.-3-4/G.1216 primers (341 bp) (Fig. 4c). The G.257/
G.i4 primers allowed amplification of HLA-G5 (765 bp)
and HLA-G6 (489 bp) (Fig. 4d) . We thus confirmed that
all HLA-G mRNA had been transcribed in M8-HLA-
G*0105N cell line.
HLA-G Proteins Are Translated in HLA-G*0105N-
Transfected Cells
The proteins synthesized by the HLA-G*0105N allele
have been deduced from its nucleotide sequence [14]. Ac-
cording to these authors, HLA-G isoform amino-acid se-
quences deduced from the HLA-G*0105N DNA sequence
would yield the complete membrane-bound HLA-G2 and
-G3, as well as the soluble HLA-G6 and -G7 isoforms.
HLA-G1, -G4, and -G5 undergo a reading frame shift, and
the corresponding proteins are prematurely truncated in the
null allele.
To detect HLA-G proteins that were expressed by M8-
HLA-G*0105N in our experiments, we carried out immu-
nocytochemistry assays on permeabilized cells. As may be
seen in Figure 5, M8-HLA-G*0105N cells were positively
stained by 4H84, an antibody that targets the a1 domain
present in all HLA-G isoforms (Fig. 5b); by MEM-G/04,
an antibody that recognizes the a3 domain (Fig. 5f); and
by 5A6G7, an antisoluble antibody against HLA-G5 and
-G6) (Fig. 5n). As expected, the presence of HLA-G1 or
-G5 was not detected in M8-HLA-G*0105N with the MEM-
G/09 antibody (Fig. 5j). All these anti-HLA-G antibodies
had positively bound M8-HLA-G*010102, a genomic
HLA-G sequence in which HLA-G1 is predominantly ex-
pressed, but one would expect the other isoforms to be
present (Fig. 5, c, g, k, and o). The HLA-G2 isoform was
stained by both the 4H84 and the MEM-G/04 antibodies in
M8-HLA-G2 cells (Fig. 5, d and h). Collectively, these im-
munocytochemical analyses revealed the presence of HLA-
G2 and -G6 isoforms in M8-HLA-G*0105N.
Using flow cytometry and the MEM-G/09 antibody, we
confirmed that whereas M8-HLA-G*0105N did not express
HLA-G1 protein at the cell surface, M8-HLA-G*010102
did (Fig. 6). Because of the unavailability of antibodies able
to bind HLA-G2 and HLA-G3 in the flow cytometry assay,
we were unable to identify these membrane-bound iso-
forms, which could have been translated by M8-HLA-
G*0105N cells.
Characterization of HLA-G Proteins in HLA-G*0105N-
Transfected Cells
In succeeding experiments, we attempted to characterize
the HLA-G proteins that had been translated in M8-HLA-
G*0105N cells, using M8-HLA-G*010102 and M8-HLA-
G2 as positive controls. We used immunoprecipitation of
biotinylated cell-surface proteins to achieve separation of
membrane-bound and intracytoplasmic proteins. The results
revealed membrane-bound HLA-G2 protein on M8-HLA-
G2 (bands at 30 and 27 kDa) and HLA-G1 protein on M8-
HLA-G*010102 (one band at 43 kDa), but no HLA-G mol-
ecules could be detected in M8-HLA-G*0105N by this
method (Fig. 7A). However, study of the intracellular pro-
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FIG. 5. Immunocytostaining of M8 trans-
fectants with anti-HLA-G antibodies 4H84
(a–d), MEM-G/04 (e–h), MEM-G/09 (i–l),
and 5A6G7 (m–p). All antibodies are neg-
ative in the control M8-pcDNA (a, e, i,
m). The anti-HLA-G1, -G2, -G5, -G6 anti-
body MEM-G/04 is positive in all HLA-G
transfected cells (f–h). The anti-HLA-G1, -
G5 antibody MEM-G/09 stained M8-HLA-
G*010102 (k) but not M8-HLA-G*0105N
(j) or M8-HLA-G2 (l). The anti-HLA-G5, -
G6 antibody 5A6G7 stained M8-HLA-
G*0105N (n) and M8-HLA-G*010102 (o)
but not M8-HLA-G2 (p). Original magnifi-
cation 3200.
FIG. 6. Detection by flow cytometry analysis of the HLA-G1 isoform on M8-HLA-G*010102 but not on M8-HLA-G*0105N. Cells were labeled by
indirect immunofluorescence with MEM-G/09 mAb (bold profiles) and an isotope-matched control Ab (light profiles). M8-pcDNA and M8-HLA-G1
cells were used as controls.
teins revealed the presence of HLA-G isoforms. We ob-
tained three bands, one at 30 kDa and one at 27 kDa, that
were identical to those produced by M8-HLA-G2, plus one
located above them, at 35 kDa, that has never been char-
acterized (Fig. 7B). To determine whether this latter band
corresponded to hyperglycosylated HLA-G2, we treated the
M8-HLA-G*0105N cells with PNGase F, an enzyme that
catalyzes the removal of N-linked oligosaccharide chains
from glycoproteins (Fig. 8). This enzyme treatment re-
vealed a smaller band just below that of the mature protein,
corresponding to the deglycosylated protein. This finding
indicated that M8-HLA-G*0105N had indeed translated
some glycoproteins, but the molecular weight obtained for
the 35-kDa protein did not correspond to any known HLA-
G isoform. Staining with 4H84 and MEM-G/04 antibodies
allowed us to determine that at least the a1 and a3 domains
were present in this protein, which remains to be charac-
terized.
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FIG. 7. The HLA-G*0105N allele produced intracytoplasmic HLA-G
proteins. Cell-surface proteins are biotinylated and separated from the
nonbiotinylated inside proteins. Immunostaining with both 4H84 and
MEM-G/04 mAbs revealed the intracellular presence of HLA-G proteins
(B) but not on the cell surface (A). The mechanism providing the addi-
tional smaller band for HLA-G2 (i.e., band at 27 kDa) remains to be
determined. FIG. 8. HLA-G*0105N isoforms are translated as glycoproteins. Lysate
from M8 transfectants were treated with PNGase F allowing visualization
of mature and deglycosylated proteins. Western blots were stained with
4H84 mAb. PNGase F treatment removed oligosaccharides from the gly-
coproteins. Revelation of two bands (glycosylated and not) indicated that
this treatment was not complete. M8-HLA-G*0105N presents two weak
bands, at 30 and 27 kDa (representing glycosylated and nonglycolysated
HLA-G2) and one unidentified band at 35 kDa, which migrated at 31
kDa after PNGase F treatment.
HLA-G*0105N-Transfected Cells Are Protected from NK
Cell-Mediated Cytotoxicity
To determine whether the HLA-G*0105N allele translat-
ed functional HLA-G isoforms, cytotoxic assays were car-
ried out confronting either the NKL or the YT2C2 cell line
[17, 19] used as the effector with the M8 or U937 trans-
fectant cells used as the target (Fig. 9). When stimulated
with interleukin-2, the NKL human NK cell line retained
most of the original features of NK cells, including very
similar proliferative responses and natural killing function.
While YT2C2 express only KIR2DL4, NKL cells express
both ILT2 and KIR2DL4 inhibitory receptors [18, 26],
which are implicated in the NK-cell cytotoxicity pathways,
by binding to HLA-G molecules. The lytic activity of NKL
against M8-HLA-G*0105N was compared with its lytic ac-
tivity against M8-HLA-G*010102 cells, which at least ex-
press HLA-G1, as well as against M8-HLA-G2 cells, which
express only the HLA-G2 isoform, and against M8-pcDNA,
used as the HLA-G-negative control. Cytotoxicity experi-
ments showed that in addition to M8-HLA-G2, both geno-
mic M8-HLA-G*0105N and M8-HLA-G*010102 were pro-
tected from NKL lysis. Lysis of M8-transfectants was re-
duced by 50% compared with that of the M8-pcDNA con-
trol cell line. Inhibition of cytotoxicity was also obtained
using YT2C2 cells, which only express the HLA-G-specific
receptor against U937-transfectants.
DISCUSSION
After our study of the tolerogeneic role of HLA-G in
maternal-fetal tolerance [27, 28], we designed experiments
to identify the structural and functional characteristics of
proteins generated by the HLA-G*0105N allele. First, we
used site-directed mutagenesis to construct the HLA-
G*0105N from the nucleotide sequence of HLA-G*010102
and transfected it into the M8 human cell line. Then we
characterized the transcripts and proteins generated by the
HLA-G*0105N gene before analyzing the functional capac-
ity of the isoforms produced.
Although the deletion of one base in exon 3 of HLA-
G*0105N disrupts the reading frame, it should have no ef-
fect on transcription of the primary transcript or on its al-
ternative splicing [14]. Indeed, in our RT-PCR analysis, the
HLA-G mRNA profile was the same in both M8-HLA-
G*0105N- and M8-HLA-G*010102-transfected cells, indi-
cating the presence of all HLA-G mRNA transcripts nor-
mally found. Thus, deletion of the cytosine in codon 130
did not block the transcription and splicing mechanisms in
the null allele. Nevertheless, real-time and classical RT-
PCR showed that HLA-G mRNA levels were lower in M8-
HLA-G*0105N than in M8-HLA-G*010102 cells, and clas-
sical PCR revealed that the HLA-G1/HLA-G2 mRNA ratio
was lower in M8-HLA-G*0105N than in M8-HLA-
G*010102. This discrepancy in the expression level of
HLA-G genotypes and isoforms has already been reported
for alleles other than the null allele in pathological preg-
nancies in which altered HLA-G transcription was associ-
ated with certain HLA-G genotypes [29, 30] as well as in
a study of the role of HLA-G alleles in determining the
soluble HLA-G protein plasma level [31]. Another expla-
nation is that nonsense-mediated decay, a eukaryotic reg-
ulatory process that degrades mRNA with premature ter-
mination codons, could be responsible for the higher deg-
radation of HLA-G1 transcripts in cells expressing the null
allele compared with other alleles [32].
Furthermore, the higher levels of mRNA in transfected
cells compared with JEG-3 cells could be explained by the
fact that 1) in transfected cells, HLA-G is ligated in the
pcDNA3.1 plasmid, which possesses the CMV promoter
and is thus able to influence and perhaps increase HLA-G
mRNA expression, and 2) HLA-G*010102 has been de-
scribed as a much higher ‘‘HLA-G secreting’’ allele than
either HLA-G*0105N or HLA-G*010103 (carried by JEG-
3 cells [33]) [31].
Finally, although mRNA levels are higher in M8-trans-
fected cells than in JEG-3 cells, this cannot be correlated
with either the quality or the quantity of the corresponding
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FIG. 9. M8-HLA-G*0105N is able to in-
hibit NKL cell cytolytic activity. Chromium
release assays were carried out using M8-
or U937-pcDNA, M8- or U937-HLA-
G*0105N, M8- or U937-HLA-G*010102,
or M8-HLA-G2 as target cells and NKL
cell line (A) or YT2C2 cell line (B) as ef-
fectors. Results are expressed as the per-
centage lysis recorded in a 4-h 51Cr-release
assay. Values represent means of triplicate
6 SD. This experiment is representative of
five distinct experiments.
translated isoform proteins. Thus, the mRNA level is lower
in M8-HLA-G*0105N cells than in M8-HLA-G010102
cells (Fig. 3), and both M8 transfectants are equally pro-
tected from NKL-mediated cytolysis (Fig. 9A).
Since the presence of HLA-G mRNA had been demon-
strated in M8-HLA-G*0105N, we also looked for HLA-G
proteins in it. For this purpose, HLA-G*0105N-transfected
cells were immunostained with specific HLA-G antibodies
targeting either all HLA-G proteins or specific isoforms. As
expected from the deletion in HLA-G*0105N, neither the
HLA-G1 nor the HLA-G5 isoform was detected in M8-
HLA-G*0105N since these cells were not stained by the
MEM-G/09 mAb, which is specific for HLA-G1 and HLA-
G5. The absence of HLA-G5 and of shed HLA-G1 was
confirmed by a specific ELISA (data not shown). Interest-
ingly, the other mAbs that recognized either all HLA-G
isoforms (4H84), both HLA-G5 and -G6 (5A6G7), or HLA-
G1, -G2, -G5, and -G6 (MEM-G/04) were positive in M8-
HLA-G*0105N, demonstrating that in the absence of both
HLA-G1 and -G5, other HLA-G isoforms are produced.
These isoforms may correspond to at least the HLA-G2
and/or HLA-G6 proteins. In support of this observation,
previous immunohistochemical analyses of placentas ho-
mozygous for HLA-G*0105N presented negative staining
with an anti-HLA-G1, -G5 antibody (87G) and positive
staining with an anti-HLA-G1, -G2 antibody (15C6) [15].
These results confirm that HLA-G proteins are indeed
translated in HLA-G*0105N cells.
To further characterize the HLA-G isoforms produced
by M8-HLA-G*0105N cells, we carried out immunoprecip-
itation and Western blot experiments. Under our experi-
mental conditions, proteins at 35 and 30 kDa were detected
within such cells but not on the cell surface. However, we
cannot exclude that HLA-G proteins are secreted by these
cells and that they exercise biological effects. To address
this point, we carried out experiments aimed at analyzing
the role of the HLA-G proteins generated by M8-HLA-
G*0105N with respect to NK function and tested their ca-
pacity to inhibit NK cell lysis.
Considered together, these results demonstrate that non-
HLA-G1/-G5 isoforms of the HLA-G*0105N allele partic-
ipate in the inhibition of NK cells. This inhibition is per-
haps not mediated by HLA-E or other HLA class I mole-
cules, since HLA-G*0105N-transfected cells were protected
from lysis by the NK-like clone Y2T2C2. Indeed Y2T2C2
expresses the HLA-G-specific receptor KIR2DL4, but not
HLA-A-, -B-, -C-, and -E-specific KIRs.
The HLA-G*0105N allele is estimated to have appeared
18 000 yr ago, leading to the conclusion that it had been
positively selected during evolutionary history [16]. A high
incidence of the null allele has notably been reported in
Africa [34]. A possible explanation for this selection is that
it may be due to the high incidence of intrauterine patho-
gens among the Africa population, which therefore has to
maintain an efficient immune system to eliminate uterine
infections [16]. One would expect that the absence of HLA-
G1 and -G5 in HLA-G*0105N individuals would serve to
maintain the immunocompetence of maternal NK and T
cells at the maternal-fetal interface [15, 16]. Weighing the
trade-off between increased risk of miscarriage due to the
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absence of HLA-G1 and -G5 but low risk of uterine infec-
tion and successful outcome of pregnancy but high risk of
womb infection, HLA-G*0105N was selected over HLA-
G1, -G5, thus eradicating intrauterine pathogen contami-
nation despite the fact that the null genotype is a contrib-
uting factor in spontaneous abortion [35, 36]. Our results
suggest that HLA-G*0105N would be of interest for pur-
poses other than merely preventing interactions between
HLA-G1, -G5 and inhibitory NK receptors since HLA-G2
has maintained that function. The advantages of the selec-
tion of this allele must be further investigated.
The emergence of the HLA-G*0105N homozygous gene
is not the only condition under which HLA-G protein ex-
pression has been found to be impaired. As for classical
HLA-class I molecules, both HLA-G1 and -G5 contain
three globular domains associated with b2m and present
peptides. Their conformation renders these HLA molecules
TAP and b2m dependent. Therefore, in TAP- or b2m-de-
ficient individuals, NK-mediated reactions may still occur,
and NK cells may retain the ability to reject allogeneic and
autologous HLA-class I-negative cells. However, studies of
such individuals showed that HLA-class I-deficient cells
remain protected from NK lysis. Notably, there are other
situations in which expression of both HLA-G1 and -G5
isoforms would also be altered without negatively affecting
the outcome of pregnancy. One example is the survival of
homozygous TAP-negative children in whom one would
expect HLA-G1/-G5 placental expression to be impaired.
Indeed, expression of these two isoforms as a trimolecular
a-chain/b2m/peptide complex is TAP dependent. In the fe-
tuses of such TAP-negative children, the other HLA-G iso-
forms, whose expression may be independent of peptide
loading via TAP, may substitute for the loss of HLA-G1/-
G5, thus contributing to the survival of these fetuses [37].
In another study, functional analyses indicated that
TAP2/2 NK cells were unable to kill autologous class I-
negative cells. This inhibition was attributed to an unknown
inhibitory receptor capable of binding ligand expressed by
targeted autologous class I-negative cells, thereby down-
regulating NK cell cytotoxicity [38]. Considered together,
these studies suggest that still-unknown mechanisms pre-
vent an attack against autologous normal cells that express
insufficient quantities of HLA-class I molecules. Therefore,
the HLA-G2, -G3, -G6, and -G7 isoforms, in which cell
processing and transport are probably peptide independent,
might be candidate molecules to compensate for the loss of
HLA class I antigens, including HLA-G1 and -G5. The fact
that TAP2/2 NK cells express an unidentified receptor sug-
gests that this unidentified inhibitory receptor is specific for
spliced HLA-G isoforms. These interpretations could be ex-
trapolated to tumor cells, which often present down-regu-
lation of classical and nonclassical HLA class I molecules.
Expression of the TAP and b2m-independent spliced HLA-
G isoforms (HLA-G2 through -G7) observed in some tu-
mors may constitute a new escape mechanism from NK
cell-mediated lysis [39].
Finally, our study provided information indicating that
HLA-G*0105N does not encode the complete HLA-G1 or
HLA-G5 isoforms but does encode functional HLA-G pro-
teins able to inhibit NK cell cytolysis. Thus, although the
biological functions of HLA-G1 and HLA-G5 proteins are
abrogated, the other isoforms can assume their roles. Two
different effectors were used against M8-transfectant cells:
the NKL and YT2C2 cells. Since NKL cells expressed
ILT2, KIR2DL4, and CD94/NKG2A receptors, lysis of
HLA-G*0105N cells could be due to a direct interaction
between HLA-G and ILT2 or KIR2DL4 receptors and/or to
a indirect effect through HLA-E (whose surface expression
is up-regulated in presence of HLA-G leader peptide) and
CD94/NKG2A. Nevertheless, results obtained with the
YT2C2 effector cells demonstrate that at least HLA-G pro-
teins expressed by HLA-G*0105N inhibit NK lysis through
direct interaction with KIR2DL4. Our results showing that
HLA-G*0105N cells retained the capacity to inhibit NK cy-
totoxicity activity agree with the previously described in-
hibitory role played by the HLA-G2 and -G3 [4]. In support
of a biological role for other HLA-G isoforms than -G1 and
-G5, two recent reports found that 1) HLA-G2 and -G6
isoforms are expressed by specific subpopulations of tro-
phoblast cells [40] and that 2) recombinant HLA-G6 in-
duces TGF-b production by monocytic lineage cells [41].
Most classical HLA-class I genes are translated into one
isoform. Therefore, a mutation in the gene yields a null
allele, which results in the disappearance of this HLA mol-
ecule. A feature of the HLA-G gene is that it encodes seven
isoforms, including some that are not altered in the null
genotype (HLA-G2/-G3/-G6/-G7). Thus, HLA-G*0105N
could maintain the presence of functional HLA-G proteins.
In this respect, it would be important to determine the func-
tion of each HLA-G isoform and whether a specific role
may be attributed to each of them in pregnancy as well as
in tumors and transplants.
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